Asia One13d
Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session at WCLC 2024
Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically ...
Immunotherapy Clinical Trials - A New Approach to Treating Cancer
Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments for ...
KOIN 613d
Akeso's Ivonescimab Head-to-Head Phase III Data Against Pembrolizumab Unveiled at WCLC 2024
Currently, a Phase III study of ivonescimab monotherapy versus pembrolizumab monotherapy ... regimen as first-line treatment for pancreatic cancer. Overall, ivonescimab is engaged in over ...
Innovation Driving Cancer's Solid Tumors Market
According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, exhibiting a growth ...